<DOC>
	<DOCNO>NCT01722396</DOCNO>
	<brief_summary>Previous study vitamin D supplementation suggest may differences response individual . This study open label study vitamin D supplementation patient active latent tuberculosis active disease patient take 100000units vitamin D every 8 week tuberculosis treatment . Genotyping relevant vitamin D pathway polymorphism carry related clinical ex vivo marker vitamin D response . Latent patient study vitamin D response ex vivo . Our hypothesis response vitamin D monocytes T cell related polymorphism DBP gene , may relate clinical response term post supplementation vitamin D level .</brief_summary>
	<brief_title>Pharmacogenetics Vitamin D Supplementation Tuberculosis</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Age 16 Microbiologically histologically confirm active tuberculosis Clinically confirm latent tuberculosis 1 . Patients manage regime outside standard NICE guidance 2 . Drug resistant MTb 3 . HIV positive 4 . Known intolerance vitamin D 5 . Sarcoidosis 6 . Hyperparathyroidism nephrolithiasis 7 . Taking vitamin D supplementation two month precede enrolment 8 . Baseline serum correct calcium &gt; 2.65 mmol/L 9 . Current haemodialysis 10 . Children , pregnant breastfeeding individual 11 . Concomitant benzothiadiazine derivative , cardiac glycoside , carbamazepine , phenobarbital , phenytoin , primidone longterm immunosuppressant therapy</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>